Navigation Links
PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
Date:7/27/2009

NES-ZIONA, Israel, July 27, /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH) formerly Modigene Inc., today announced that it has entered into an evaluation and option agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science. Under the terms of the evaluation and option agreement, PROLOR may obtain from Yeda a license to develop a number of peptide drug candidates, including an anti-obesity peptide, utilizing a delivery technology developed at the Weizmann Institute. The Weizmann Institute of Science is a world-renowned center of natural and exact sciences research and higher learning based in Rehovot, Israel.

"The Weizmann Institute produces world-class research and this agreement, enabling us to access novel technology developed by their scientists, represents an exciting opportunity for PROLOR," said Shai Novik, president of PROLOR. "The first preclinical drug candidate we will evaluate under the agreement is a potential long-acting anti-obesity compound. Obesity represents a large and growing worldwide health care crisis, and there is an urgent need for effective and safe weight loss therapies. We believe the timing is right for us to explore entering this market with a drug candidate that may have strong competitive advantages over other anti-obesity approaches currently in development."

Further details of the agreement were not disclosed.

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, proprietary versions of already approv
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
2. PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
3. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
4. Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan
5. Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets
6. Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders
7. The MedZilla Report: June 2009 Employment Outlook for Biotech/Pharma/Health
8. Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)
9. Dow AgroSciences, NemGenix Establish New Collaboration in Plant Biotechnology
10. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
11. Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... According to a new market ... Medicine (Bone and Joint) Market (By Technology - ... Applications - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic ... Analysis, Size, Share, Growth, Trends and Forecast, 2013 ... joint) market was valued at USD 2.6 billion ...
(Date:7/28/2014)... 28, 2014 According ... Market by Products (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, ... (Detection, Characterization) - Global Forecasts to 2019" ... is estimated at $896.5 Million in 2014 ... by 2019, growing at a CAGR of ...
(Date:7/28/2014)... Appistry, Inc. , a leading ... power of genomics to next-generation medicine, announced today its ... . , Two Appistry staff will be joined ... for Genome Resources, and Mr. Neil Miller, director of ... City. Rounding out the panel are Appistry’s Dr. Richard ...
(Date:7/28/2014)... , July 28, 2014   The Atlas ... 4-star boutique hotel in the heart of The Atlas Town Center ... Photo - http://photos.prnewswire.com/prnh/20140725/130455 Photo - ... ATLAS , The Atlas ... suites, a sleek restaurant and bar, a wellness spa, a grand ...
Breaking Biology Technology:Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4
... With employee performance module implemented in just few months, ... ... personal growth, ... of web-based employee performance and talent management software,today announced that ...
... Transave Inc.,reported today that its lead product ... ability to penetrate mucus and,biofilms, and decrease the ... cystic fibrosis, according to results of a study ... of the study titled "Biofilm penetration, triggered release ...
... March 31 Profect(TM) Medical,Technologies, a leading ... clinical photography systems, today announced the introduction ... hiring of Holly Smith as its,Director., ... with an,array of customized photographic and software ...
Cached Biology Technology:Beaumont Hospitals in Michigan Selects Halogen Software for Pay for Performance System 2Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 2Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 3Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 4Holly Smith Joins Profect as Director of Clinical Imaging Services 2
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
(Date:7/28/2014)... Research Hospital study found that 73 percent of adult ... of developing metabolic syndrome and related health problems by ... in the current issue of the journal Cancer ... survivors of childhood cancer in the study had metabolic ... high blood pressure, abdominal obesity, elevated triglyceride and other ...
(Date:7/28/2014)... 2014 Research and Markets has ... Latin America 2014-2018" report to their offering. ... measure and analyze biological data. These systems capture biological ... voice patterns, and hand measurements from the subject and ... The main purpose of a biometrics system is to ...
Breaking Biology News(10 mins):New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3Biometrics Market in Latin America 2014-2018 2
... The behavior of marine larvae is central to fully understanding ... organisms. For the first time, a numerical study conducted by ... skills into realistic 3D flow fields, creating a powerful tool ... their way back to the reef after being out on ...
... & Science division of Thomson Reuters, the world,s ... professionals, today announced the launch of its ... a new initiative aimed at enabling access to ... developed with third-party partners. Through the ...
... Africa could benefit from access to treatment for an endemic ... of infection. Researchers tested hundreds of children aged between ... fever also known as bilharzia or schistosomiasis is ... they are perceived to be at low risk of exposure ...
Cached Biology News:Fish larvae find the reef by orienting: The earlier the better 2Fish larvae find the reef by orienting: The earlier the better 3Thomson Reuters Launches Life Sciences Partner Ecosystem to Drive Collaborative R&D Drug Processes 2Treatment to benefit African infants at risk of endemic fever 2
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: